Clinical trial · Observational
Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial
NCT02817685CI-TRIAL-00022775unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a randomized control prospective study. The aim of this study is to establish an all-round and convenient follow-up strategy of Chronic Hepatitis B for early detection and diagnosis of Hepatocellular Carcinoma (HCC), by investigating whether different surveillance time intervals and surveillance methods are beneficial for chronic hepatitis B and cirrhotic patients with different risk of HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Hepatitis B | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3 months | Other | — | UNRESOLVED |
| 3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI | Other | — | UNRESOLVED |
| 6 months | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- 1
- description
- Chronic Hepatitis B patient
- interventionNames
- Other: 3 months
- label
- 2
- description
- Chronic Hepatitis B patient
- interventionNames
- Other: 6 months
- label
- 3
- description
- cirrhotic patient
- interventionNames
- Other: 3 months
- label
- 4
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. HBV-Ag positive( \>6 months) 2. age among 18 and 80 years Exclusion Criteria: 1. patients with hepatocellular carcinoma 2. patients were diagnosis hepatocellular carcinoma within 3 months of inclusion; 3. patients with alcoholic hepatitis or autoimmune hepatitis 4. patients with severe uncontrolled disease resulting in estimated life expectance less than 1 year 5. coinfection with human immunodeficiency virus(HIV) 6. cannot undergo contrast-enhanced imaging 7. refuse attending the study
References
Publications (0)
Data not yet available
No reference posted for this study.